SGS Lab in Italy Earns cGMP Accreditation
SGS Life Science Services has been awarded cGMP accreditation from AIFA for its analytical laboratory in Livorno, Italy.
SGS Life Science Services has been awarded cGMP accreditation from AIFA (Agenzia Italiana del Farmaco) for its new analytical laboratory, at its Livorno, Italy facility, the company’s first dedicated life science laboratory in Italy.
The new facility will focus on analytical quality control testing, IT compliance and validation, and complement the existing service offer at the Livorno site, which provides facilities qualification, calibration and validation services, and an analytical chemistry laboratory.
The 1085 sq m laboratory employs 25 staff, is ISO 9001 accredited, and completes the SGS Life Science Services offering for the Italian market, according to a company press statement. cGMP accreditation enables the Livorno GMP laboratory to demonstrate, on behalf of it clients, whether or not individual batches of raw materials, or of regulated product, are manufactured according to the highest quality standards.
Source: SGS Life Science Services
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
